Page 1

RaySearch : Laboratories INTERIM REPORT JANUARY 1 - SEPTEMBER 30 , 2021 " In the third quarter of 2021 , license revenue rose 37 percent and support revenue rose 12 percent . Overall , net sales rose 15 percent and operating loss totaled SEK -27 M [ -29 ] . " Johan Löf , CEO of RaySearch . THIRD QUARTER ( JULY - SEPTEMBER 2021 ) Order intake SEK 127.9 M ( 138.5 ) Net sales SEK 136.4 M [ 119.1 ) Operating loss SEK -26.6 M ( -29.5 ) Loss after tax SEK -22.0 M ( -26.2 ) ● ● ● SIGNIFICANT EVENTS DURING THE THIRD QUARTER The RayStation® treatment planning system was sold to more leading cancer centers , including National Cancer Centre Singapore ( NCCS ) , Centro de Tratamiento e Investigación sobre cáncer Luis Carlos Sarmiento Angulo ( CTIC ) in Colombia , and Queen Elizabeth Hospital ( QEH ) in Hong Kong . In addition , Iridium Network in Belgium expanded its existing RayStation installation . ● Loss per share before / after dilution SEK -0.64 ( -0.76 ) Cash flow SEK - 10.1 M [ pos : 21.7 ) Order backlog SEK 1,211.6 M ( 1,228.5 ) at the end of the period ● In September , Iridium Network in Belgium , one of RaySearch's development partners for RayCare , decided to invest in RayCare as its primary oncology information system . In September , RayStation was taken into clinical use together with Accuray's CyberKnife therapy device at Centre hospitalier universitaire vaudois ( CHUV ) in Switzerland . THE COVID - 19 PANDEMIC The COVID - 19 pandemic with temporary reorganizations in healthcare also had a negative impact on sales in the third quarter . RaySearch expects that the negative effects of the COVID - 19 pandemic on the company's sales and earnings will continue for some months to come , mainly because orders may be delayed . SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD In October , RayCare was taken into clinical use with Accuray's Radixact® treatment delivery system at Swiss Medical Network in Switzerland . ● RaySearch and IBA are expanding their collaboration around proton therapy in the areas of FLASH radiotherapy , proton arc therapy and the treatment of tumors in motion . ● RaySearch and Mevion Medical Systems are expanding their collaboration on the development of treatment planning methods for FLASH radiotherapy with the Mevion S250i Proton Therapy System . FINANCIAL SUMMARY¹ NINE MONTHS ( JANUARY - SEPTEMBER 2021 ) Order intake SEK 462.7 M ( 615.6 ) ● Net sales SEK 453.1 M ( 491.8 ) Operating loss SEK -36.8 M ( profit : 11.1 ) Loss after tax SEK - 31.3 M ( profit : 5.1 ) Loss per share before / after dilution SEK -0.91 ( earnings : 0.15 ) Cash flow SEK -51.6 M [ pos : 83.4 ) ● When access is granted to the new head office premises in the fourth quarter of 2021 , total assets are expected to increase approximately SEK 466 M in accordance with IFRS 16 . • Torbjörn Wingårdh was appointed new CFO of RaySearch as of November 15 , 2021 . AMOUNTS IN SEK 000s Net sales Operating profit / loss Operating margin , % Profit / loss for the period Earnings / loss per share before / after dilution , SEK Cash flow from operating activities Cash flow for the period Return on equity , % Equity / assets ratio , % , at the end of the period Share price at the end of the period , SEK ¹ For definitions of key ratios , see page 20 . JUL - SEP 2021 136,419 -26,561 -19.5 -21,990 -0.64 47,356 -10,088 -3.2 56.7 61.5 ADVANCING CANCER TREATMENT 2020 119,130 -29,477 -24.7 -26,182 -0.76 78,486 21,720 -3.7 57.0 87.7 JAN - SEP 2021 453,100 -36,763 -8.1 -31,347 -0.91 209,765 -51,638 -4.6 56.7 61.5 2020 491,777 11,126 2.3 5,084 0.15 280,003 83,388 0.7 57.0 87.6 OCT 2020 SEP 2021 612,935 -51,355 -8.4 -45,511 -1.33 265,851 -73,136 -6.7 56.7 61.5 FULL - YEAR 2020 651,612 -3,466 -0.5 -9,080 -0.26 331,508 61,890 -1.3 54.0 82.7